



## **Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval**

December 3, 2025 1:00 PM EST

*Humana and UnitedHealthcare, which granted authorization in November, are the two largest Medicare Advantage providers in the U.S., accounting for 47% of all Medicare Advantage enrollees*

*This latest approval will help enhance timely access to cutting-edge personal exoskeleton solutions for individuals with spinal cord injury*

*Reimbursement coverage is expected to give Lifeward stronger revenue and cash flow dynamics to scale growth*

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- [Lifeward Ltd.](#), (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that it received prior authorization from Humana Medicare Advantage Plan for a [ReWalk 7](#) Personal Exoskeleton. This marks the second national Medicare Advantage Plan, following [UnitedHealthcare](#) a few weeks ago, to make the important decision to support members living with spinal cord injury by facilitating access to this life-changing technology.

By approving coverage for the ReWalk 7 under its Medicare Advantage Plan, Humana continues to show leadership in embracing innovative medical technologies and widening reimbursement pathways for beneficiaries. The approval reflects Humana's dedication to meeting the needs of members with disabilities and their families, providing more reliable and predictable access to personal exoskeletons as part of a comprehensive care strategy.

"Nationally nearly half of all Medicare Advantage enrollees are now eligible for prior authorization and reimbursement for ReWalk 7," said Mark Grant, CEO of Lifeward. "This prior authorization approval from a Humana Medicare Advantage Plan represents another significant milestone in payer adoption of the ReWalk Exoskeleton. As coverage broadens and prior authorizations accelerate, we are seeing stronger predictability in reimbursement, healthier cash flow dynamics, and a clearer foundation for scalable, sustainable growth in the U.S. market."

In 2024, the Centers for Medicare & Medicaid Services (CMS) implemented a formal reimbursement pathway for personal exoskeletons. Since then, Lifeward has continued to submit claims on behalf of beneficiaries enrolled in both traditional Medicare and Medicare Advantage Plans. As payer adoption expands, the Company is experiencing an accelerating pace of prior authorization approvals, an encouraging signal of growing recognition of the clinical and functional value of personal exoskeleton technology.

### **About Lifeward**

Lifeward designs, develops, and commercializes life-changing solutions spanning the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings, as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products, including the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System. Founded in 2001, Lifeward has operations in the United States, Israel, and Germany.

Lifeward®, ReWalk®, ReStore®, and AlterG® are registered trademarks of Lifeward Ltd. and/or its affiliates.

### **Forward-Looking Statements**

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. Important factors that could cause the Company's actual results to differ materially from those indicated in the forward looking statements include, among others: the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; the impact of reimbursements on Lifeward's revenue and cash flow; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company's ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer and transitioning the manufacturing of its ReWalk products to its in-house manufacturer; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company's annual report on Form 10-K, as amended, for the year ended December 31, 2024 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company's actual

results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Lifeward Media Relations:

Almog Adar

Chief Financial Officer

E: [media@golifeward.com](mailto:media@golifeward.com)

Lifeward Investor Contact:

Almog Adar

Chief Financial Officer

Lifeward

E: [ir@golifeward.com](mailto:ir@golifeward.com)



Source: Lifeward Ltd.